BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, November 25th.

BioLineRx Trading Down 1.1 %

Shares of BLRX stock opened at $0.22 on Thursday. The company has a market cap of $17.71 million, a PE ratio of -1.01 and a beta of 1.39. BioLineRx has a 1 year low of $0.19 and a 1 year high of $1.64. The stock’s 50 day simple moving average is $0.34 and its two-hundred day simple moving average is $0.54. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Hedge Funds Weigh In On BioLineRx

Several institutional investors have recently made changes to their positions in the company. CVI Holdings LLC purchased a new stake in BioLineRx during the second quarter valued at approximately $462,000. PVG Asset Management Corp acquired a new position in shares of BioLineRx in the 2nd quarter valued at about $70,000. Finally, Atria Investments Inc boosted its position in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares in the last quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.